Brief Introduction
Medizone International, Inc. (OTCBB: MZEI) is a research and development company engaged in developing AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools, clean rooms, hotels, cruise ships and other critical infrastructure. Hospital beta testing of the production prototype was conducted in October 2010. The trial results were deemed to be highly successful.
Annual Shareholder Meeting
- Medizone held its annual meeting of shareholders on August 26, 2009 in Reno, Nevada
- Directors were elected -- Edwin G. Marshall, Richard G. Solomon, Daniel D. Hoyt, Dr. Michael E. Shannon
- For the first time since the company became a public company in 1986 the shareholders voted to increase the number of shares the company is authorized to issue
- A modest portion of the newly authorized shares were earmarked to facilitate the financing of the October 2010 hospital beta testing and initial production of the company's AsepticSure™ hospital sterilization system
- The availability of increased authorized capital has also provided management greater flexibility for strategic development
The Company is currently engaged in preparation for phase two hospital beta testing, bed bug trials and bio-terrorism countermeasures trials. It is also preparing for the FIME Show in August this year (2011).
Initial Sales of AsepticSure™
- Commencement of commercial deliveries is anticipated late in 2011
- Medizone's target is to achieve profitability moving into early 2012.
Partnership with Multinational Corporation
Following proof of reliability of the first commercially delivered units, Medizone will have optimized its strengths as a research and development company. It then expects to partner with a large corporation embedded in the hospital sector for increased:
- Manufacturing capacity
- Sales
- Service
Entries(RSS)